National Pension Service Sells 293,155 Shares of Moderna, Inc. (NASDAQ:MRNA)

National Pension Service lessened its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 36.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 520,738 shares of the company’s stock after selling 293,155 shares during the period. National Pension Service’s holdings in Moderna were worth $21,652,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB increased its holdings in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after purchasing an additional 587 shares in the last quarter. Venturi Wealth Management LLC increased its holdings in Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after purchasing an additional 664 shares in the last quarter. Compass Planning Associates Inc bought a new position in Moderna during the 4th quarter worth about $37,000. Larson Financial Group LLC increased its holdings in Moderna by 53.5% during the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after purchasing an additional 317 shares in the last quarter. Finally, Rakuten Securities Inc. increased its holdings in Moderna by 477.3% during the 3rd quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock worth $63,000 after purchasing an additional 778 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on MRNA shares. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $40.00 target price on shares of Moderna in a research note on Tuesday, February 18th. Berenberg Bank raised their target price on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. Barclays downgraded shares of Moderna from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $111.00 to $45.00 in a research note on Tuesday, February 18th. Finally, Morgan Stanley cut their price objective on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 15th. Four research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Moderna presently has an average rating of “Hold” and a consensus target price of $60.63.

Moderna Stock Performance

NASDAQ MRNA opened at $30.96 on Friday. The firm’s fifty day moving average price is $37.30 and its two-hundred day moving average price is $51.12. The stock has a market cap of $11.94 billion, a PE ratio of -3.34 and a beta of 1.59. Moderna, Inc. has a fifty-two week low of $29.25 and a fifty-two week high of $170.47.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.